ALLO - Allogene reports positive early-stage data for CAR T candidates in blood cancer

Allogene Therapeutics (ALLO) announced positive data from two Phase 1 clinical trials for ALLO-501 and ALLO-501A in relapsed/refractory non-Hodgkin lymphoma ((NHL)). The experimental anti-CD19 allogeneic CAR T therapies are developed in partnership with Servier.The data will be featured in poster presentations at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting to be held June 4 – 8.In the ALPHA trial of ALLO-501 in combination with ALLO-647, 42 patients were enrolled and 41 received ALLO-501 including nine of those who had previously received autologous CAR T treatment.In those who were not treated with CAR T therapy, “response rates were similar to those seen in autologous CAR T therapy trials,” the company said.Longer terms data from the trial “demonstrate for the first time the ability of an off-the-shelf cell therapy to induce durable responses in NHL patients similar to that seen in trials of autologous therapies,” commented Rafael Amado chief medical officer at

For further details see:

Allogene reports positive early-stage data for CAR T candidates in blood cancer